$UNH · Parkev Tatevosian, CFA · 2026-11-11
UNH 仍是买入机会:公司正从 2025 年的成本定价失误中恢复,长期 EPS 增长预期已回升至 14.2% 以上,落在管理层 13-16% 的目标区间内;同时高成本仍在持续,退出市场和提价正在减少客户。当前远期市盈率为 17,低于 2025 年前的水平并接近长期 EPS 增速,DCF 估值为 532 美元,而现价为 396 美元,因此看起来被低估;尽管没有哪只股票是无风险的,但风险回报比值得承担。
播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策
逐段跳播
UnitedHealth Group 正在从2025年所面临的巨大困难中恢复过来。要记得,在那一年,公司低估了服务客户的成本,因此没有为保单合理定价,导致公司的盈利能力和自由现金流大幅下降。
UnitedHealth Group is recovering from the enormous difficulties it faced in 2025. Remember that in that year, the company underestimated the cost of serving its customers and therefore did not price its policies appropriately, resulting in a significant decrease in the company's profitability and free cash flow .
股价大幅下跌,管理团队告知投资者,我们将从2026年开始做出调整,情况会好转,而到目前为止,今年确实如此。所以,要为管理团队点赞。事实上,情况比管理团队预期的还要好一些。所以这非常积极,股价也对此作出了反应。
2026年年初以来它已经上涨了近20%,我对此很高兴,因为我曾把它评为买入机会。
The share price fell sharply, and the management team informed investors that we would be making adjustments starting in 2026 and things would improve, and this has turned out to be the case so far this year.
So, a shout-out to the management team . In fact, things went a little better than the management team had expected. So this was very positive, and the stock price responded to it .
It has risen by nearly 20% since the beginning of the year in 2026, and I am happy about that because I rated it as a buying opportunity.
所以我想重新评估这家公司,看看在现在的11月它是否仍是买入机会,还是股价已经涨得太高,不再是有吸引力的持仓。
So I wanted to reassess the company, to see if it was still a buying opportunity now in November, or if the share price had risen so high that it was no longer an attractive position.
一个有趣的事实是,UnitedHealth Group 几乎已经让华尔街相信了它的长期盈利增长前景,不是吗?去年,当她正经历自己的挑战时,她告诉华尔街分析师,我们相信从长期来看,我们能够连续数年将每股收益提高13%到16%。我们相信我们能够持续做到这一点。
An interesting fact is that UnitedHealth Group has almost convinced Wall Street of its long-term earnings growth prospects, hasn't it? Last year, when she was going through her challenges, she was telling Wall Street analysts that we believe in the long run that we can increase earnings per share by 13 to 16% for several consecutive years. We believe we can do that consistently.
当时,华尔街分析师说:“不,我们认为你们做不到。”你可以看到这反映在每股收益增长预期上,这些预期已经跌至持平或负增长的水平,不是吗?因此,华尔街分析师并不相信 UnitedHealth Group 真的能在未来几年实现两位数的每股收益增长。
At that time, Wall Street analysts were saying, "No, we don't think you can do that," and you can see that reflected in earnings per share growth estimates that have collapsed to a flat or negative level, can't you ?
Therefore, Wall Street analysts were not confident that UnitedHealth Group could truly achieve double-digit earnings per share growth for the next few years.
但你可以看到,2026年情况已经发生了变化。看看每股收益预期被上调得有多快,现在它们已经回到14.2%以上,正好处于管理团队13%到16%预期的中间位置。
But you can see that the situation has changed here in 2026. Look how quickly the earnings per share estimates have been revised upwards, and they are now back to over 14.2%, which is exactly in the middle of the management team’s estimates of between 13 and 16%.
所以,他们几乎已经完全让投资者相信,他们有能力实现他们所暗示能够达成的长期增长,这一点他们在两周前与华尔街分析师举行会议时再次予以确认。他们说:“13%到16%,我们仍然对实现这一目标的能力有信心。”
So they have almost completely convinced investors of their ability to deliver the long-term growth they suggested they could achieve, a point they reaffirmed two weeks ago when they held a meeting with Wall Street analysts .
They said: "From 13 to 16%, we are still confident in our ability to reach this goal."
所以在2026年,他们还能够用公司产生的一部分现金流偿还部分债务。年初时他们的长期债务总额约为800亿美元,现在长期债务略高于714亿美元。这意味着减少了约90亿美元,略高于其长期债务的10%,这应该会降低利息支出、增加自由现金流,并让管理团队拥有更多流动性来进一步偿债或回购股票,而他们在过去12到18个月里一直在积极回购。
So in 2026, they were also able to use some of the cash flow the company had generated to pay off some of the debt. They started the year with about $80 billion of total long-term debt, and now have just over $71.4 billion of long- term debt.
This represents a reduction of about $9 billion , or slightly more than 10% of their long-term debt, which should reduce interest expenses, increase free cash flow , and give the management team more liquidity to pay down more debt or repurchase shares, which they have been doing aggressively over the past 12 to 18 months.
评级有所改善,但并不显著。UnitedHealth 股票目前的远期市盈率为17倍,仍低于2025年陷入困难之前的水平。
The rating improved, but not significantly. UnitedHealth stock is now trading at a forward P/E ratio of 17, which is still lower than it was before the 2025 difficulties.
我认为部分原因是成本的结构性上升仍然存在,对吧?所以,并不是说,管理团队在2025年面临困难的原因之一,就是他们低估了客户服务的高成本。
I think that's partly because the structural increases in costs are still there, right? So, it's not as you know, one of the reasons the management team faced difficulties in 2025 was that they underestimated the high costs of customer service.
所以在2026年,他们更准确地估算了客户服务成本。成本并没有下降,但管理团队变得更有能力估算这些成本,因此他们没有低估它们。所以,他们能够做出更好地反映高成本环境的经营决策。然而,高成本仍在继续对业务造成负面影响。
他们有选择地退出某些市场并提高定价政策,最终导致所服务的客户数量减少。
So in 2026, they estimated the cost of customer service more accurately. Costs did not decrease , but the management team became more capable of estimating those costs, so they did not underestimate them .
Therefore, they were able to make business decisions that better reflected the high-cost environment . However, high costs continue to negatively impact the business. They have selectively chosen to exit certain markets and raise pricing policies, ultimately resulting in a decrease in the number of customers being served.
所以,这一问题仍部分存在,并引起投资者的一些担忧,因此与2025年之前的水平相比,17倍远期市盈率的估值仍然相对较低。
So , this is still partially present and causing some concern for investors, and therefore the valuation is still relatively low compared to pre- 2025 levels at a forward P/E ratio of 17.
但我认为这是一个有吸引力的估值,因为它非常接近公司13%到16%的长期每股收益增长预期。所以今天我更新了对 UnitedHealth Group 的贴现现金流评估,计算出公司每股价值532美元。当前市场价格为每股396美元。
But I think this is an attractive valuation because it is very close to the company’s long-term earnings per share growth estimates of 13% to 16%. So today I also updated my discounted cash flow assessment for UnitedHealth Group , and calculated that the company is worth $532 per share. The current market price is $396 per share.
因此,无论你是基于远期市盈率来看,还是使用贴现现金流模型,这只股票看起来都被低估了。为了回答我在引言中提出的问题,我仍然认为这只股票代表着买入机会。我今天通过我的评级确认了这一点。
Therefore, whether you look at it based on the forward price-to-earnings ratio or using a discounted cash flow model, the stock appears to be undervalued. To answer the question I posed in the introduction, I still believe that the stock represents a buying opportunity. I confirmed that through my ranking today.
但当然,没有哪只股票是没有风险的。总是存在风险,但我认为在这种情况下,风险回报比是值得的。
But of course, no stock is risk-free. There are always risks involved, but I believe the risk-reward ratio is worthwhile in this situation.
这个频道对 $UNH 的历次判断
Parkev Tatevosian, CFA 在这只股票上共 2 条判断,这里只列相邻的几条。